GalNAc-Lipid Nanoparticles Enable Non-LDLR-Dependent Hepatic Delivery of CRISPR Therapy
A study demonstrates that GalNAc-Lipid nanoparticles can achieve efficient liver-targeted delivery of CRISPR base editing therapy, offering a potential option for treating familial hypercholesterolemia and other liver diseases. Key Highlights…
GalNAc-Lipid Nanoparticles Enable Non-LDLR-Dependent Hepatic Delivery of CRISPR Therapy
A study demonstrates that GalNAc-Lipid nanoparticles can achieve efficient liver-targeted delivery of CRISPR base editing therapy, offering a potential option for treating familial hypercholesterolemia and other liver diseases. Background Challenges…